Clinical Trials on Primary Immune Deficiency Disorders (PIDD)

Total 47539 results

ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Therapure Biopharma Inc

Unknown

Study of PlasmaCap IG in Adults and Children With PIDD

Primary Immune Deficiency Diseases (PIDD)

United States, Canada
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
BriovaRx Infusion Services
Bio Products Laboratory (BPL)

Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Primary Immunodeficiency Disease (PIDD)

United States
University Hospital, Strasbourg, France

Completed

Severe PID With Lymphoproliferation and Neutropenia (DICEP)

Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)

France
Shire

Completed

Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID) (IG-TATRY)

Primary Immunodeficiencies (PID)

Poland
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Primary Immunodeficiency Diseases (PID)

Canada
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Johns Hopkins All Children's Hospital

Recruiting

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Metabolic Disease | Primary Immune Deficiency Disorders

United States
Children's National Research Institute

Recruiting

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC)

Viral Infection | Hematopoietic Stem Cell Transplantation (HSCT) | Primary Immunodeficiency Disorders (PID)

United States
Takeda

Recruiting

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Primary Immunodeficiency Diseases (PID)

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Octapharma

Completed

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID)

France
University Hospital, Caen

Completed

Pediatric Intensive Care Unit and Primary Immune Deficiency (PICUPID)

Immuno-Deficiency

France
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Primary Immune Deficiency Disorder | Bone Marrow Failure | Immune Deficiency Disease

United States
Baxalta now part of Shire

Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Primary Immunodeficiency Diseases (PID) | Hypogammaglobulinemia | Agammaglobulinemia

Finland, Sweden
University Hospital, Caen

Completed

Intensive Care Unit and Secondary and Primary Immune Deficiency (ICUSPID)

Primary Immune Deficiency Disorder

France
National Institute of Allergy and Infectious Diseases...
University of Pittsburgh; PPD

Completed

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant (BOLT-BMT)

Primary Immunodeficiency | PID

United States
Octapharma

Completed

Octagam 5% Versus Comparator Post Marketing Trial

Primary Immune Deficiency Disorder

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Antibody Production in Immune Disorders

Primary Immune Deficiency

United States
University of Zurich

Recruiting

Identification of New Inborn Errors of Immunity

Primary Immune Deficiency Disorder

Switzerland
Octapharma

Completed

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

United States
Octapharma

Completed

Study of Octanorm Subcutaneous IG in Patients With PID

Primary Immune Deficiency Disorder

United States, Canada, Czechia, Hungary, Poland, Russian Federation, Slovakia
University of Zurich

Recruiting

Pathophysiology of Inborn Immunodeficiencies

Primary Immune Deficiency Disorder

Switzerland
Green Cross Corporation

Withdrawn

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency Disorder
Kuwait Society for Allergy and Clinical Immunology

Completed

Primary Immunodeficiency in Kuwait

Primary Immune Deficiency Disorder

Kuwait
Karolinska University Hospital

Completed

Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency (VITAPID)

Primary Immune Deficiency Disorder

Sweden
Octapharma

Completed

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

Russian Federation
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
Instituto Grifols, S.A.

Completed

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

Primary Immune Deficiency Disease

United States
ADMA Biologics, Inc.

Completed

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Primary Immune Deficiency Disorder

United States
Federal Research Institute of Pediatric Hematology...

Completed

TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID

Primary Immune Deficiency Disorder | Hematopoietic Stem Cell Transplantation

Russian Federation
ADMA Biologics, Inc.

Active, not recruiting

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Primary Immune Deficiency Disorder

United States
Caja Costarricense de Seguro Social

Completed

Primary Immunodeficiencies in Costa Rican Adults

Primary Immune Deficiency in Adults

Costa Rica

Clinical Trials on Primary Immune Deficiency Disorders (PIDD)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations